Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Share-based Compensation (2023 - 2025)

Kura Oncology (KURA) has disclosed Share-based Compensation for 3 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 31.53% to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.1 million, a 9.47% increase, with the full-year FY2025 number at $37.1 million, up 9.47% from a year prior.
  • Share-based Compensation was $11.4 million for Q4 2025 at Kura Oncology, up from $11.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $11.4 million in Q4 2025 to a low of $6.8 million in Q1 2023.
  • A 3-year average of $8.3 million and a median of $8.1 million in 2024 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 31.73% in 2025; the steepest drop was 17.57% in 2025.
  • Kura Oncology's Share-based Compensation stood at $7.2 million in 2023, then increased by 20.43% to $8.6 million in 2024, then soared by 31.53% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Share-based Compensation are $11.4 million (Q4 2025), $11.0 million (Q3 2025), and $6.9 million (Q2 2025).